Alvotech Business Summary

Alvotech (ALVO) is a vertically integrated biotechnology company specializing exclusively in the development and large-scale manufacture of biosimilar medicines. The company generates revenue through a hybrid model of direct product sales and strategic commercial partnerships, which provide upfront payments, R&D milestones, and profit-sharing royalties. Its primary business segments are centered on its end-to-end biosimilar platform, covering the entire value chain from cell line development to sterile fill-finish manufacturing. Alvotech’s portfolio targets high-value biologics in immunology, oncology, and ophthalmology, with five products already marketed globally and a pipeline of 30 candidates. Its primary direct competitors include Sandoz, Amgen, Celltrion, and Formycon; Alvotech distinguishes itself as a pure-play biosimilar specialist, leveraging its Icelandic manufacturing hub to offer a more cost-efficient, vertically integrated alternative to diversified pharmaceutical giants. Founded in 2013 by Róbert Wessman, the company is led by an executive team with deep pedigree in the generics and biologics sectors. Wessman, who previously transformed Actavis into a global leader and founded Alvogen, currently serves as Chairman and CEO, though he is transitioning to a full-time Executive Chairman role by the end of Q1 2026. His successor, Lisa Graver, was appointed CEO in January 2026, bringing over 25 years of experience from her previous role as CEO of Alvogen. Other key leaders include CFO Linda Jónsdóttir, COO Joseph McClellan, and Chief Strategy Officer Balaji Prasad. The company is backed by a robust roster of institutional investors and strategic partners, including BlackRock, Vanguard, the Healthcare of Ontario Pension Plan (HOOPP), and Baxter Healthcare, while its board features industry veterans such as Deputy Chairman Richard Davies.